A Slicer-independent role for Argonaute 2 in hematopoiesis and the microRNA pathway

Dónal O’Carroll, Ingrid Mecklenbrauker, Partha Pratim Das, Ulrich Koenig, Anton J. Enright, Eric A. Miska, and Alexander Tarakhovsky

1The Laboratory for Lymphocyte Signaling, The Rockefeller University, New York, New York 10021, USA; 2Wellcome Trust/Cancer Research, UK Gurdon Institute and Department of Biochemistry, University of Cambridge, Cambridge CB2 1QN, United Kingdom; 3Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, United Kingdom

Binding of microRNA (miRNA) to miRNA within the RNA-induced silencing complex (RISC) leads to either translational inhibition or to destruction of the target mRNA. Both of these functions are executed by Argonaute 2 (Ago2). Using hematopoiesis in mice as a model system to study the physiological function of Ago2 in vivo, we found that Ago2 controls early development of lymphoid and erythroid cells. We show that the unique and defining feature of Ago2, the Slicer endonuclease activity, is dispensable for hematopoiesis. Instead, we identified Ago2 as a key regulator of miRNA homeostasis. Deficiency in Ago2 impairs miRNA biogenesis from precursor-miRNAs followed by a reduction in miRNA expression levels. Collectively, our data identify Ago2 as a highly specialized member of the Argonaute family with an essential nonredundant Slicer-independent function within the mammalian miRNA pathway.

Results and Discussion

The potent regulatory function of miRNA in hematopoiesis (Chen et al. 2004; Cobb et al. 2005; Fazi et al. 2005; Muljo et al. 2005) makes this process attractive for the investigation of the physiological significance of Ago2. We therefore studied the development of the lymphoid and erythroid lineages derived from Ago2−/− bone marrow cells. The latter cells were produced by inducible inactivation of the Ago2 gene in bone marrow progenitors followed by the generation of Ago2−/− hematopoietic system in lethally irradiated wild-type mice (Supplementary Fig. S1). This approach enables the analysis of the bone marrow cell-intrinsic Ago2 function. Mice reconstituted with Ago2−/− or control Ago2fl/fl bone marrow cells are hereafter referred to as Ago2−/− or Ago2fl/fl mice, respectively.

Analysis of mice 6–8 wk after reconstitution revealed that Ago2−/− bone marrow cells give rise to hematopoietic cells of various lineages [data not shown]. However, the differentiation of the B lymphoid as well as erythroid lineages diverges significantly from the wild-type developmental pattern. Deficiency in Ago2 does not interfere with the generation of early pro-B (B220loCD43+IgM−) cells in the bone marrow, but affects further pre-B (B220loCD43−IgM−) cell differentiation and the subsequent generation of peripheral B cells [Fig. 1A; Table 1]. Among various hematopoietic lineages in the bone marrow, erythroid cells appear to be most affected. The maturation of the Ago2−/− erythroid precursors is severely impaired. This developmental defect is characterized by a dramatic increase in the frequencies and numbers of immature Ter119+CD71+CD11b− basophilic erythroblasts and decrease in frequencies and numbers of Ter119loCD71− mature orthochromatophilic erythroblasts in the bone marrow and spleens of Ago2−/− mice [Fig. 1B, Table 1]. Ago2−/− mice display erythroid hyperplasia in both the bone marrow and spleen [Fig. 1B]. The combination of ineffective erythropoiesis and erythroid hyperplasia results in splenomegaly in Ago2−/− mice [Fig.
1D. The defective erythropoiesis in the absence of Ago2 fails to generate fully functional red blood cells (RBCs). Ago2−/− mice develop severe anemia characterized by a reduction in the overall number of erythrocytes as well as the amount of hemoglobin per erythrocyte (Fig. 1C). Ago2−/− RBCs, but not control erythrocytes, contained Heinz bodies, inclusion bodies that contain Hb precipitates (Fig. 1E). The same phenotype was observed at 3 mo after reconstitution (data not shown). Therefore, these alterations do not represent a stress response to the transfer but rather reflects the long lasting consequence of Ago2 deficiency.

To directly test the physiological significance of “slicing,” we evaluated the ability of bone marrow cells deficient for Ago2’s “Slicer” endonuclease activity to support erythropoiesis in the bone marrow. For these purposes, we employed the Ago2D669A point mutant that is endonuclease inactive in vitro (Liu et al. 2004) and in vivo (Supplementary Fig. S2). Ago2−/− bone marrow cells were complemented with exogenous wild-type or Slicer-inactive Ago2 and used to generate bone marrow chimeras. Exogenous wild-type Ago2 and Slicer-inactive Ago2 were expressed at similar levels in both the bone marrow and bone marrow-derived splenic cells of reconstituted mice (Supplementary Fig. S3A). Most importantly, expression of either wild-type Ago2 or Slicer-inactive Ago2 could cure the impaired erythropoiesis and anemia caused by Ago2 deficiency. The expression of Slicer-inactive Ago2 restored the wild-type pattern of erythroid development in the bone marrow and spleen, rescuing ineffective erythropoiesis, erythroid hyperplasia, and splenomegaly (Fig. 2A; Supplementary Fig. S3C). In addition, expression of the Slicer-inactive Ago2 in Ago2−/− cells restored erythroid parameters and prevented Heinz body formation to the same degree as exogenous wild-type Ago2 (Fig. 2C; Supplementary Fig. S3B). Similar to the erythroid cells, expression of Slicer inactive Ago2 was able to support normal B-cell development in the bone marrow (Fig. 2B). These results show the dispensable role of Ago2’s slicer function in regulation of erythropoiesis and B-cell lymphopoiesis.

Table 1. B and erythroid precursor numbers in Ago2−/− mice

<table>
<thead>
<tr>
<th></th>
<th>Ago2fl/fl</th>
<th>Ago2−/−</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>B lymphoid</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pro B (B220loCD43IgM−)</td>
<td>1.4 ± 0.36</td>
<td>0.62 ± 0.44</td>
<td>0.07</td>
</tr>
<tr>
<td>Pre B (B220loCD43IgM−)</td>
<td>7.28 ± 2.2</td>
<td>0.74 ± 0.23</td>
<td>0.011</td>
</tr>
<tr>
<td>Immature B (B220loIgM+)</td>
<td>05.2 ± 1.6</td>
<td>0.85 ± 0.39</td>
<td>0.012</td>
</tr>
<tr>
<td>Mature B (B220loIgM+)</td>
<td>05.6 ± 1.6</td>
<td>2.3 ± 0.78</td>
<td>0.032</td>
</tr>
<tr>
<td><strong>Erythroid</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Bone marrow</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Basophilic erythroblasts (Ter119hiCD71lo)</td>
<td>13.4 ± 1.50</td>
<td>26.9 ± 1.27</td>
<td>0.0002</td>
</tr>
<tr>
<td>Chromatophilic erythroblasts (Ter119hiCD71med)</td>
<td>1.43 ± 0.27</td>
<td>2.62 ± 0.32</td>
<td>0.0007</td>
</tr>
<tr>
<td>Orthochromatophilic erythroblasts (Ter119hiCD71hi)</td>
<td>1.25 ± 0.35</td>
<td>0.15 ± 0.06</td>
<td>0.0094</td>
</tr>
<tr>
<td><strong>Spleen</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Basophilic erythroblasts (Ter119hiCD71lo)</td>
<td>0.8 ± 0.5</td>
<td>186 ± 34</td>
<td>0.0032</td>
</tr>
<tr>
<td>Chromatophilic erythroblasts (Ter119hiCD71med)</td>
<td>1.82 ± 0.9</td>
<td>13.8 ± 2.7</td>
<td>0.0011</td>
</tr>
<tr>
<td>Orthochromatophilic erythroblasts (Ter119hiCD71hi)</td>
<td>5.2 ± 1.5</td>
<td>2.1 ± 0.5</td>
<td>0.0120</td>
</tr>
</tbody>
</table>

Numbers of B-lymphoid cell populations in the bone marrow and erythroid cell populations in the bone marrow and spleen of Ago2fl/fl and Ago2−/− mice. The frequency of the fraction of the nucleated cells was determined by flow cytometry and was used to calculate the total number of cells. Data shown are means in units of 10^6 cells with standard deviations from n = 4 mice. The significance, P value, derived from a t-test, is shown.
Figure 2. Ago2 control of hematopoiesis is Slicer independent. (A,B) Slicer-inactive Ago2 supports wild-type B-cell development and erythropoiesis. Representative FACS profiles of erythroid (A) and B-lymphoid (B) populations derived from bone marrow chimeras generated with Ago2−/− cells transduced with control vector (Migr), exogenous Ago2 [Migr-Ago2], or slicer-inactive Ago2 [Migr-Ago2D669A]. Transduced cells identified by the expression of GFP are shown. Numbers indicate the percentages of gated cells. (C) Slicer-inactive Ago2 normalizes erythrocyte parameters in the peripheral blood. The frequencies [percentage of live cells] of bone marrow GFP+ cells in bone marrow chimeras used for the analysis are shown. (RBC) Red blood cell; (Hb) hemoglobin; (HCT) hematocrit; (MCV) mean cell volume; (MCH) mean corpuscular hemoglobin; (RDW) red cell distribution width.

The irrelevance of Ago2-mediated slicing in hematopoiesis suggested an additional and essential role for Ago2 in the miRNA pathway. Earlier studies pointed to the potential involvement of Ago2 in miRNA homeostasis. Ago2 directly binds miRNA and is a component of the ribonucleoprotein complex that mediates miRNA biogenesis [Chendrimada et al. 2005; Gregory et al. 2005; Grace et al. 2005]. Ago2 interacts with Dicer in vivo, and this protein complex possesses pre-miRNA processing activity in vitro [Maniataki and Mourelatos 2005]. The dispensability of Ago2’s Slicer activity in miRNA biogenesis is supported by the fact that Slicer-inactive Ago2 interacts with Dicer in vivo, and this protein complex possesses pre-miRNA processing activity in vitro [Maniataki and Mourelatos 2005]. The defective miRNA biogenesis cannot be attributed to the reduced expression of Dicer that is expressed at normal levels in Ago2−/− cells [Fig. 4D]. These data suggest that absence of Ago2 from RISC hampers either access of Dicer to pre-miRNA or reduces its overall enzymatic activity. The interaction of Ago2 with Dicer through the TRBP and PACT couples miRNA biogenesis with the loading of RISC. It is possible that the absence of Ago2 impairs RISC function in a fashion similar to RISC malfunction caused by reduced expression of PACT or TRBP (Chendrimada et al. 2005; Gregory et al. 2005; Haase et al. 2005; Lee et al. 2006). We demonstrate that Ago2 has an earlier function within RISC in facilitating miRNA biogenesis, this is also sup-

hepatocytes display a reduction in miRNA expression levels [Fig. 3B,C].

The arrested biogenesis of miRNA caused by the absence of Dicer is associated with accumulation of some but not all pre-miRNAs (Yi et al. 2006). Therefore, the accumulation of pre-miR-24 and pre-miR-199a in Ago2−/− fibroblasts, two pre-miRNAs that are readily detectable in wild-type fibroblasts, indicates a crucial role for Ago2 in miRNA biogenesis [Fig. 4A]. The impaired miRNA biogenesis is independent of Ago2’s Slicer activity, as complementation of Ago2−/− cells with slicer-inactive Ago2 restores miRNA biogenesis [Fig. 4B,C]. The dispensability of Ago2’s Slicer activity in miRNA biogenesis is supported by the fact that Slicer-inactive Ago2 interacts with Dicer in vivo, and this protein complex possesses pre-miRNA processing activity in vitro [Maniataki and Mourelatos 2005]. The defective miRNA biogenesis cannot be attributed to the reduced expression of Dicer that is expressed at normal levels in Ago2−/− cells [Fig. 4D]. These data suggest that absence of Ago2 from RISC hampers either access of Dicer to pre-miRNA or reduces its overall enzymatic activity. The interaction of Ago2 with Dicer through the TRBP and PACT couples miRNA biogenesis with the loading of RISC. It is possible that the absence of Ago2 impairs RISC function in a fashion similar to RISC malfunction caused by reduced expression of PACT or TRBP (Chendrimada et al. 2005; Gregory et al. 2005; Haase et al. 2005; Lee et al. 2006). We demonstrate that Ago2 has an earlier function within RISC in facilitating miRNA biogenesis, this is also su-

Figure 3. Ago2 controls miRNA expression levels. Reduced miRNA expression levels in the absence of Ago2. The levels of miRNA expression in Ago2−/− and Ago2−/− erythroblasts (A), fibroblasts (B), or hepatocytes (C) were measured by miRNA array profiling [top] and qRT–PCR [bottom]. [Top panels] Heat maps of miRNA expression from the Ago2−/− and Ago2−/− cells are shown. Two independent preparations [Sample 1 and 2] or, in the case of fibroblasts, cell lines 4 and 9, are shown. Increased or decreased amount of miRNA relative to the median are indicated in red and green, respectively; normalized fold changes are indicated in the color bar. Ranges in the color bar refer to gene standard deviations. [Bottom panels] Expression levels of two representative miRNAs were quantified by qRT–PCR. The U6 normalized expression of miRNAs in mutant cells is shown. Numbers indicate the percentages of gated cells. (RBC) Red blood cell; (Hb) hemoglobin; (HCT) hematocrit; (MCV) mean cell volume; (MCH) mean corpuscular hemoglobin; (RDW) red cell distribution width.

The arrested biogenesis of miRNA caused by the absence of Dicer is associated with accumulation of some but not all pre-miRNAs (Yi et al. 2006). Therefore, the accumulation of pre-miR-24 and pre-miR-199a in Ago2−/− fibroblasts, two pre-miRNAs that are readily detectable in wild-type fibroblasts, indicates a crucial role for Ago2 in miRNA biogenesis [Fig. 4A]. The impaired miRNA biogenesis is independent of Ago2’s Slicer activity, as complementation of Ago2−/− cells with slicer-inactive Ago2 restores miRNA biogenesis [Fig. 4B,C]. The dispensability of Ago2’s Slicer activity in miRNA biogenesis is supported by the fact that Slicer-inactive Ago2 interacts with Dicer in vivo, and this protein complex possesses pre-miRNA processing activity in vitro [Maniataki and Mourelatos 2005]. The defective miRNA biogenesis cannot be attributed to the reduced expression of Dicer that is expressed at normal levels in Ago2−/− cells [Fig. 4D]. These data suggest that absence of Ago2 from RISC hampers either access of Dicer to pre-miRNA or reduces its overall enzymatic activity. The interaction of Ago2 with Dicer through the TRBP and PACT couples miRNA biogenesis with the loading of RISC. It is possible that the absence of Ago2 impairs RISC function in a fashion similar to RISC malfunction caused by reduced expression of PACT or TRBP (Chendrimada et al. 2005; Gregory et al. 2005; Haase et al. 2005; Lee et al. 2006). We demonstrate that Ago2 has an earlier function within RISC in facilitating miRNA biogenesis, this is also su-

Figure 3. Ago2 controls miRNA expression levels. Reduced miRNA expression levels in the absence of Ago2. The levels of miRNA expression in Ago2−/− and Ago2−/− erythroblasts (A), fibroblasts (B), or hepatocytes (C) were measured by miRNA array profiling [top] and qRT–PCR [bottom]. [Top panels] Heat maps of miRNA expression from the Ago2−/− and Ago2−/− cells are shown. Two independent preparations [Sample 1 and 2] or, in the case of fibroblasts, cell lines 4 and 9, are shown. Increased or decreased amount of miRNA relative to the median are indicated in red and green, respectively; normalized fold changes are indicated in the color bar. Ranges in the color bar refer to gene standard deviations. [Bottom panels] Expression levels of two representative miRNAs were quantified by qRT–PCR. The U6 normalized expression of miRNAs in mutant cells is shown. Numbers indicate the percentages of gated cells. (RBC) Red blood cell; (Hb) hemoglobin; (HCT) hematocrit; (MCV) mean cell volume; (MCH) mean corpuscular hemoglobin; (RDW) red cell distribution width.

The arrested biogenesis of miRNA caused by the absence of Dicer is associated with accumulation of some but not all pre-miRNAs (Yi et al. 2006). Therefore, the accumulation of pre-miR-24 and pre-miR-199a in Ago2−/− fibroblasts, two pre-miRNAs that are readily detectable in wild-type fibroblasts, indicates a crucial role for Ago2 in miRNA biogenesis [Fig. 4A]. The impaired miRNA biogenesis is independent of Ago2’s Slicer activity, as complementation of Ago2−/− cells with slicer-inactive Ago2 restores miRNA biogenesis [Fig. 4B,C]. The dispensability of Ago2’s Slicer activity in miRNA biogenesis is supported by the fact that Slicer-inactive Ago2 interacts with Dicer in vivo, and this protein complex possesses pre-miRNA processing activity in vitro [Maniataki and Mourelatos 2005]. The defective miRNA biogenesis cannot be attributed to the reduced expression of Dicer that is expressed at normal levels in Ago2−/− cells [Fig. 4D]. These data suggest that absence of Ago2 from RISC hampers either access of Dicer to pre-miRNA or reduces its overall enzymatic activity. The interaction of Ago2 with Dicer through the TRBP and PACT couples miRNA biogenesis with the loading of RISC. It is possible that the absence of Ago2 impairs RISC function in a fashion similar to RISC malfunction caused by reduced expression of PACT or TRBP (Chendrimada et al. 2005; Gregory et al. 2005; Haase et al. 2005; Lee et al. 2006). We demonstrate that Ago2 has an earlier function within RISC in facilitating miRNA biogenesis, this is also su-
Ago2 deficiency selectively impairs miRNA biogenesis. (A) Pre-miRNA accumulation in Ago2−/− fibroblast cell lines. The expression levels of pre-miRNA and miRNA were measured by Northern blotting using probes specific for miR-24 and miR-199a*. U6 snRNA was used as a loading control. The positions of pre-miRNA and miRNA are indicated. The U6 normalized fold increase in the pre-miRNA expression levels in the indicated Ago2−/− cells is plotted as fold reduction over the level of miRNA expression in the respective control cell lines. (B) Pre-miR-24 and pre-miR-199a were measured and presented as in A. The U6 normalized fold increase in pre-miRNA expression levels in the indicated Ago2−/− reconstituted cell lines relative to Ago2−/− cells complemented with wild-type Ago2 are indicated. (C) Expression levels of two representative miRNAs were quantified by qRT-PCR. The U6 normalized expression of miRNAs in Ago2−/− cells complemented as indicated is plotted as fold reduction over the level of miRNA expression in Ago2+/+ cells complemented with wild-type Ago2. (D) Unaltered expression of Dicer in the absence of Ago2. The expression of Dicer in Ago2−/− fibroblasts was confirmed by immunoblotting with an α-Tubulin antibody. Protein loading was controlled with an α-Tubulin antiserum. (E,F) Normal expression of pre-miRNA and miRNA in Ago1- and Ago3-deficient fibroblast cell lines. (E) Total RNA was isolated from Ago1−/−, Ago1+/−, Ago3−/−, and Ago3+/− fibroblast cell lines. The expression levels of pre-miR-24 and pre-miR-199a were measured by Northern blotting and presented as above. (F) Expression levels of two representative miRNAs were quantified by qRT–PCR. The U6 normalized expression of miRNAs in the Ago1−/− and Ago3−/− cells is plotted as fold reduction over the level of miRNA expression in the respective control cell lines.

Materials and methods

Generation of an Ago2 conditional allele in mice

The Ago2 locus contains 16 exons. The targeting strategy allows Cre-mediated deletion of exons 9–11. This deletion excludes in-frame splicing of exon 8 to exons 12–16, and leads to the functional inactivation of Ago2 due to partial deletion of the PAZ domain and loss of RNase activity. In addition, according to the rules of RNA surveillance [Hentze and Kulozik 1999], the in-frame stop codons generated by frame-shift mutations introduced by the deletion of exons 9–11 is likely to destabilize the resulting primary transcript RNA and prevent production of a truncated Ago2 protein. The Ago2 gene targeting vector (pDTA–TK–Ago2) carries a neomycin resistance (neo+) gene flanked with two frt sites, a loxp site (neo−–frt2–loxP cassette) located 3' of exon 11 and a loxp site (5’loxP) within the intron between exons 8 and 9. The Ago2 targeting construct was transfected into E14.1 embryonic stem (ES) cells. Southern blotting of the individual ES cell clone-derived genomic BamHI-digested DNA with probe 121 was used to identify homologous recombinants. A 4.2-kb DNA fragment corresponds to the wild-type Ago2 locus, and integration of the neo−–frt2–loxP cassette 3' of exon 11 introduces an additional BamHI site, thus increasing the size of the BamHI DNA fragment recognized by probe 121 to 5.0 kb. Targeted ES cells were used to generate mice heterozygous for the Ago2-targeted allele. These mice were then crossed to the FLP-expressing transgenic mouse [FLP/R] [Farley et al. 2000] to remove the frt-flanked neo+ cassette, resulting in the generation of Ago2 loxP allele (Ago2fl allele).

Generation of Ago2−/− bone marrow and analysis of bone marrow chimeras

To inactivate the Ago2 gene in the bone marrow, Ago2fl/fl mice (6–12 wk of age) that carry the MxCre transgene [Kuhn et al. 1995]/Ago2fl/fl;MxCre...
bone marrow cells derived from Ago2fl/fl mice treated with pI:pC as described above were used as control. Bone marrow-reconstituted mice were maintained on medicated water (1000 IU/mL polymixin B, 1.1 g/L neomycin sulfate) for 4 wk after reconstitution and were analyzed 6–8 wk or 3 mo after transfer. Isolation of spleen and bone marrow and subsequent FACs analysis were performed as described (Socolovsky et al. 2001; Mecklenbrauker et al. 2002). Blood parameters were analyzed using flow cytometry-based hematology (Bayer, Advia 120).

**Generation of an Ago2 antibody**
A synthetic peptide encompassing the first 25 amino acids of mouse Ago2 was coupled to KLH and was used as an immunogen in rabbits. Crude serum was obtained after the first boost and affinity-purified. This Ago2 was coupled to KLH and was used as an immunogen in rabbits.

**Cell extract preparation and immunodetection of Ago2**
Crude serum was obtained after the first boost and affinity-purified. This Ago2 was coupled to KLH and was used as an immunogen in rabbits. Blood parameters were analyzed using flow cytometry-based hematology (Bayer, Advia 120).

**Retroviral transduction of Ago2+/− cells**
The coding sequences of Ago2 and Ago2D669A were inserted into the HpaI site of MigR retroviral vector, and recombinant retroviruses were produced and used to infect Ago2+/− bone marrow or fibroblasts as described (Pear et al. 1998). Retrospective analysis of lethally irradiated mice was performed as above.

**Derivation and manipulation of mouse embryonic fibroblast (MEF) cell lines**
Two Ago2+/− MEF cell lines (MEF lines 4 and 9) were derived from E12.5 embryos, transformed with SV40 large T-antigen-expressing retrovirus, and propagated under standard culture conditions. To generate Ago2+/− MEFS, both Ago2+/− MEF clones were infected with Cre-expressing adenovirus (AdenoCre, Vector Biolabs). For the miRNA-guided cleavage assay, the same assay as described in Pillai et al. (2005) was employed.

**MiRNA expression analysis**
Total RNA was isolated using Trizol (Invitrogen) according to the manufacturer’s instructions. MiRNA array profiling was performed as described (Miska et al. 2004). For clustering, only miRNAs with expression levels at least five times above background were selected. Expression data were log-transformed, gene-centered [mean], and normalized, and hierarchical clustering was performed using a correlation matrix and centroid linkage using the Cluster 3.0 algorithm. qRT–PCR expression analysis of miRNAs was performed using mirVana qRT–PCR miRNA detection kit (Ambion) and Roche LightCycler 480. Northern blotting of miRNAs was performed as described (Lau et al. 2001).

**Acknowledgments**
We thank M. Fabry, R. Collier, A. Shet, T. Hoffmann, M. Weiss, W. Pear, O. Shestova, R. Yi, and M. Busslinger for their helpful expertise, advice, and discussions. We thank K. Saigo for the Ago2 cDNA. We acknowledge S. Buonomo for advice in generating Ago2 antisense. D.O.C. acknowledges the support of the Irvington Institute for Immunological Research and was their National Genetics Foundation Fellow. A.T. was supported by the Irene Diamond Foundation.

**References**

**Ago2 controls hematopoiesis/miRNA levels**
O’Carroll et al.


A Slicer-independent role for Argonaute 2 in hematopoiesis and the microRNA pathway

Dónal O'Carroll, Ingrid Mecklenbrauker, Partha Pratim Das, et al.

*Genes Dev.* 2007, 21: originally published online July 12, 2007
Access the most recent version at doi:10.1101/gad.1565607

**Supplemental Material**
http://genesdev.cshlp.org/content/suppl/2007/07/12/gad.1565607.DC1

**Related Content**
Life beyond cleavage: the case of Ago2 and hematopoiesis
Javier Martinez and Meinrad Busslinger

**References**
This article cites 40 articles, 22 of which can be accessed free at:
http://genesdev.cshlp.org/content/21/16/1999.full.html#ref-list-1

Articles cited in:
http://genesdev.cshlp.org/content/21/16/1999.full.html#related-urls

**License**

**Email Alerting Service**
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or click here.